Cancer-focused biotech startup OncoResponse raises $27M
Seattle-based biotech startup OncoResponse raised $14 million in venture funding and a $13 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
Founded in 2016, OncoResponse focuses on cancer treatments and examines “elite cancer responders” or people who have responded exceptionally well to checkpoint inhibition, a form of cancer immunotherapy. The company is currently in phase 1 trials for its lead drug, OR2805. The funding will help advance and move this drug into investigational new drug clinical studies.
“We greatly appreciate the additional support from our investors as we continue to make significant progress with our drug development efforts advancing immunotherapies,” Clifford Stocks, CEO of OncoResponse.